Product: EPHA2 Antibody
Catalog: AF5238
Description: Rabbit polyclonal antibody to EPHA2
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 108 kDa; 108kD(Calculated).
Uniprot: P29317
RRID: AB_2837724

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(83%), Rabbit(88%), Dog(100%)
Clonality:
Polyclonal
Specificity:
EPHA2 Antibody detects endogenous levels of total EPHA2.
RRID:
AB_2837724
Cite Format: Affinity Biosciences Cat# AF5238, RRID:AB_2837724.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ARCC2; AW545284; CTPA; CTPP1; CTRCT6; EC 2.7.10.1; Eck; Eph receptor A2; EPHA2; EPHA2_HUMAN; Ephrin receptor; Ephrin receptor EphA2; Ephrin type A receptor 2; Ephrin type-A receptor 2; Epithelial cell kinase; Epithelial cell receptor protein tyrosine kinase; Myk 2; Myk2; Sek 2; Sek2; Soluble EPHA2 variant 1; Tyrosine protein kinase receptor ECK; Tyrosine-protein kinase receptor ECK; Tyrosine-protein kinase receptor MPK-5; Tyrosine-protein kinase receptor SEK-2;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P29317 EPHA2_HUMAN:

Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g. skin, intestine, lung, and ovary.

Description:
Receptor for members of the ephrin-A family. Binds to ephrin-A1, -A3, -A4 and -A5. Plays an important role in angiogenesis and tumor neovascularization. The recruitement of VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly (By similarity). Induces apoptosis in a p53/TP53-independent, caspase-8-dependent manner.
Sequence:
MELQAARACFALLWGCALAAAAAAQGKEVVLLDFAAAGGELGWLTHPYGKGWDLMQNIMNDMPIYMYSVCNVMSGDQDNWLRTNWVYRGEAERIFIELKFTVRDCNSFPGGASSCKETFNLYYAESDLDYGTNFQKRLFTKIDTIAPDEITVSSDFEARHVKLNVEERSVGPLTRKGFYLAFQDIGACVALLSVRVYYKKCPELLQGLAHFPETIAGSDAPSLATVAGTCVDHAVVPPGGEEPRMHCAVDGEWLVPIGQCLCQAGYEKVEDACQACSPGFFKFEASESPCLECPEHTLPSPEGATSCECEEGFFRAPQDPASMPCTRPPSAPHYLTAVGMGAKVELRWTPPQDSGGREDIVYSVTCEQCWPESGECGPCEASVRYSEPPHGLTRTSVTVSDLEPHMNYTFTVEARNGVSGLVTSRSFRTASVSINQTEPPKVRLEGRSTTSLSVSWSIPPPQQSRVWKYEVTYRKKGDSNSYNVRRTEGFSVTLDDLAPDTTYLVQVQALTQEGQGAGSKVHEFQTLSPEGSGNLAVIGGVAVGVVLLLVLAGVGFFIHRRRKNQRARQSPEDVYFSKSEQLKPLKTYVDPHTYEDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSGSEGVPFRTVSEWLESIKMQQYTEHFMAAGYTAIEKVVQMTNDDIKRIGVRLPGHQKRIAYSLLGLKDQVNTVGIPI

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Dog
100
Rabbit
88
Sheep
83
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P29317 As Substrate

Site PTM Type Enzyme
Y67 Phosphorylation
K136 Ubiquitination
K141 Ubiquitination
S153 Phosphorylation
S154 Phosphorylation
K162 Ubiquitination
S373 Phosphorylation
S426 Phosphorylation
S433 Phosphorylation
N435 N-Glycosylation
T437 Phosphorylation
S570 Phosphorylation
Y575 Phosphorylation P29317 (EPHA2)
S577 Phosphorylation
K578 Ubiquitination
S579 Phosphorylation
K583 Ubiquitination
K586 Ubiquitination
T587 Phosphorylation
Y588 Phosphorylation P29317 (EPHA2)
T593 Phosphorylation
Y594 Phosphorylation P12931 (SRC) , P29317 (EPHA2)
K603 Ubiquitination
C612 S-Nitrosylation
K617 Ubiquitination
Y628 Phosphorylation P29317 (EPHA2)
K629 Ubiquitination
K639 Ubiquitination
K646 Ubiquitination
T647 Phosphorylation
K649 Ubiquitination
K655 Ubiquitination
Y685 Phosphorylation
K686 Ubiquitination
T692 Phosphorylation
Y694 Phosphorylation P29317 (EPHA2)
S712 Phosphorylation
K728 Ubiquitination
Y735 Phosphorylation P29317 (EPHA2)
S749 Phosphorylation
S756 Phosphorylation
S761 Phosphorylation
T771 Phosphorylation
Y772 Phosphorylation P29317 (EPHA2)
T773 Phosphorylation
T774 Phosphorylation
S775 Phosphorylation
K778 Ubiquitination
S790 Phosphorylation
Y791 Phosphorylation
K828 Sumoylation
S869 Phosphorylation
K873 Ubiquitination
S880 Phosphorylation
K882 Ubiquitination
T883 Phosphorylation
S892 Phosphorylation
S897 Phosphorylation P51812 (RPS6KA3) , P31749 (AKT1) , Q15418 (RPS6KA1)
T898 Phosphorylation
S899 Phosphorylation
S901 Phosphorylation
S910 Phosphorylation
Y921 Phosphorylation P29317 (EPHA2)
T922 Phosphorylation
Y930 Phosphorylation
K935 Ubiquitination
T940 Phosphorylation
K945 Ubiquitination
Y960 Phosphorylation P29317 (EPHA2)
S961 Phosphorylation

PTMs - P29317 As Enzyme

Substrate Site Source
O14493 (CLDN4) Y208 Uniprot
P29317-1 (EPHA2) S570 Uniprot
P29317 (EPHA2) Y575 Uniprot
P29317 (EPHA2) Y588 Uniprot
P29317 (EPHA2) Y594 Uniprot
P29317 (EPHA2) Y628 Uniprot
P29317 (EPHA2) Y694 Uniprot
P29317 (EPHA2) Y735 Uniprot
P29317 (EPHA2) Y772 Uniprot
P29317-1 (EPHA2) S897 Uniprot
P29317-1 (EPHA2) T898 Uniprot
P29317-1 (EPHA2) S899 Uniprot
P29317-1 (EPHA2) S901 Uniprot
P29317 (EPHA2) Y921 Uniprot
P29317 (EPHA2) Y960 Uniprot

Research Backgrounds

Function:

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand-independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.

(Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

PTMs:

Autophosphorylates. Phosphorylated on tyrosine upon binding and activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-594 are required for binding VAV2 and VAV3 while phosphorylated residues Tyr-735 and Tyr-930 are required for binding PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated residues are critical for recruitment of VAV2 and VAV3 and PI3-kinase p85 subunit which transduce downstream signaling to activate RAC1 GTPase and cell migration. Dephosphorylation of Tyr-930 by PTPRF prevents the interaction of EPHA2 with NCK1. Phosphorylated at Ser-897 by PKB; serum-induced phosphorylation which targets EPHA2 to the cell leading edge and stimulates cell migration. Phosphorylation by PKB is inhibited by EFNA1-activated EPHA2 which regulates PKB activity via a reciprocal regulatory loop. Phosphorylated at Ser-897 in response to TNF by RPS6KA1 and RPS6KA3; RPS6KA-EPHA2 signaling pathway controls cell migration. Phosphorylated at Ser-897 by PKA; blocks cell retraction induced by EPHA2 kinase activity. Dephosphorylated by ACP1.

Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by the HSP90 chaperone and regulates the receptor stability and activity through proteasomal degradation. ANKS1A prevents ubiquitination and degradation (By similarity).

Subcellular Location:

Cell membrane>Single-pass type I membrane protein. Cell projection>Ruffle membrane>Single-pass type I membrane protein. Cell projection>Lamellipodium membrane>Single-pass type I membrane protein. Cell junction>Focal adhesion.
Note: Present at regions of cell-cell contacts but also at the leading edge of migrating cells (PubMed:19573808, PubMed:20861311). Relocates from the plasma membrane to the cytoplasmic and perinuclear regions in cancer cells (PubMed:18794797).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g. skin, intestine, lung, and ovary.

Subunit Structure:

Homodimer. Interacts with SLA. Interacts (phosphorylated form) with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3); critical for the EFNA1-induced activation of RAC1 which stimulates cell migration (By similarity). Interacts with INPPL1; regulates activated EPHA2 endocytosis and degradation. Interacts (inactivated form) with PTK2/FAK1 and interacts (EFNA1 ligand-activated form) with PTPN11; regulates integrin-mediated adhesion. Interacts with ARHGEF16, DOCK4 and ELMO2; mediates ligand-independent activation of RAC1 which stimulates cell migration. Interacts with CLDN4; phosphorylates CLDN4 and may regulate tight junctions. Interacts with ACP1. Interacts (via SAM domain) with ANKS1A (via SAM domain). Interacts with CEMIP. Interacts with NCK1; may regulate EPHA2 activity in cell migration and adhesion.

(Microbial infection) Interacts with human herpes virus 8/HHV-8 glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction triggers EPHA2 phosphorylation and endocytosis, allowing virus entry.

(Microbial infection) Interacts with Epstein-Barr virus/HHV-4 glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction facilitates virus internalization and fusion.

Family&Domains:

Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Organismal Systems > Development > Axon guidance.   (View pathway)

References

1). PTIP Inhibits Cell Invasion in Esophageal Squamous Cell Carcinoma via Modulation of EphA2 Expression. Frontiers in Oncology, 2021 (PubMed: 33833989) [IF=4.7]

Application: WB    Species:    Sample: ESCC tumor sections

Figure 5 PTIP inhibits ESCC cell invasion and migration through EphA2. (A) Western blotting analysis against PTIP, EphA2, pS897-EphA2, pY588-EphA2 in PTIP knockdown(shPTIP#1, shPTIP#2) and control (shCtrl) TE1 cells. (B) IHC score for EphA2 in ESCC tumor sections. Unpaired, two-tailed Student’s t-test; **P < 0.01. (C) Representative IHC images for EphA2 in ESCC tumor sections. Low EphA2 and high EphA2 groups were divided based on the EphA2 immunostaining intensity scores mentioned in method. Cut off for high and low EphA2 expression in ESCC was defined < or > 11. (D) Percentage of invasion and non-invasion in ESCC groups. The differences between rates were tested by χ2; *P < 0.05. (E) Comparative expression between PTIP and EphA2 in ESCC samples from (B) analyzed by Pearson correlation. (F) Knockdown efficiency of shRNAs targeting PTIP and EphA2 in TE1 cells as determined by qRT-PCR. One-way ANOVA; *P < 0.05,**P < 0.01, ***P < 0.001. (G, H) The effect of PTIP and EphA2 double knockdown on the invasiveness of TE1 cells. For invasion assay, six different microscopic fields (magnification, ×10) from at least three independent experiments were examined; Relative intensities of the fields were measured (n ≥3). Representative images and statistical plots are shown; Mean ± s.d. are given for three independent experiments. One-way ANOVA; ***P <0.001. (I) ChIP-seq density profiles for PTIP in TE1 cells. Gene models are shown below the density profiles. (J, K) ChIP-qPCR primer sets marked with arrows were designed to cover regions present within (EphA2) or outside (EphA2-NC) of the EphA2 gene (C). ChIP-qPCR analyses of EphA2 binding (D). Representative images and statistical plots are shown; Mean ± s.d. are given for three independent experiments. Unpaired, two-tailed Student’s t-test; **P < 0.01.

Application: IHC    Species:    Sample: ESCC tumor sections

Figure 5 PTIP inhibits ESCC cell invasion and migration through EphA2. (A) Western blotting analysis against PTIP, EphA2, pS897-EphA2, pY588-EphA2 in PTIP knockdown(shPTIP#1, shPTIP#2) and control (shCtrl) TE1 cells. (B) IHC score for EphA2 in ESCC tumor sections. Unpaired, two-tailed Student’s t-test; **P < 0.01. (C) Representative IHC images for EphA2 in ESCC tumor sections. Low EphA2 and high EphA2 groups were divided based on the EphA2 immunostaining intensity scores mentioned in method. Cut off for high and low EphA2 expression in ESCC was defined < or > 11. (D) Percentage of invasion and non-invasion in ESCC groups. The differences between rates were tested by χ2; *P < 0.05. (E) Comparative expression between PTIP and EphA2 in ESCC samples from (B) analyzed by Pearson correlation. (F) Knockdown efficiency of shRNAs targeting PTIP and EphA2 in TE1 cells as determined by qRT-PCR. One-way ANOVA; *P < 0.05,**P < 0.01, ***P < 0.001. (G, H) The effect of PTIP and EphA2 double knockdown on the invasiveness of TE1 cells. For invasion assay, six different microscopic fields (magnification, ×10) from at least three independent experiments were examined; Relative intensities of the fields were measured (n ≥3). Representative images and statistical plots are shown; Mean ± s.d. are given for three independent experiments. One-way ANOVA; ***P <0.001. (I) ChIP-seq density profiles for PTIP in TE1 cells. Gene models are shown below the density profiles. (J, K) ChIP-qPCR primer sets marked with arrows were designed to cover regions present within (EphA2) or outside (EphA2-NC) of the EphA2 gene (C). ChIP-qPCR analyses of EphA2 binding (D). Representative images and statistical plots are shown; Mean ± s.d. are given for three independent experiments. Unpaired, two-tailed Student’s t-test; **P < 0.01.

2). The role of DNA hypomethylation in the promoter region of EphA2 and its relationship with pyroptosis in invasive breast cancer. 肿瘤, 2023

Application: IHC    Species: Human    Sample: breast cancer

Fig. 1 The expression level of EphA2 protein in normal breast tissues, paracancerous tissues and breast cancer tissues as analyzed by immunofluorescence staining (A) and Western blotting (B).

Application: WB    Species: Human    Sample: breast cancer

Fig. 1 The expression level of EphA2 protein in normal breast tissues, paracancerous tissues and breast cancer tissues as analyzed by immunofluorescence staining (A) and Western blotting (B).

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.